Incremental read-through

The market concludes the 6% difference is directionally positive for Novo but not enough to overturn Lilly's broader efficacy narrative in weight loss and glucose control. Prescribing behavior changes only modestly until more randomized or regulator-reviewed evidence emerges.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.